172P Functional precision medicine assay identifies patients with relapsed/refractory soft tissue sarcoma who benefit from bortezomib-based therapy

Puntos clave

• To determine how functional precision medicine assays can identify patients with relapsed/refractory soft tissue sarcoma who are likely to benefit from bortezomib therapy.
• Utilized functional precision medicine assays to assess patient tumors
• Evaluated response to bortezomib-based treatment
• Monitored side effects including mucositis and hyperglycemia
• Identified a subset of patients responding positively to bortezomib
• Reported significant side effects like mucositis and hyperglycemia in some cases